サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427705

運動失調症の世界市場レポート 2024

Ataxia Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
運動失調症の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

運動失調症の市場規模は、今後数年間で大幅な成長が見込まれています。2028年には8.5%の年間複合成長率（CAGR）で513億米ドルに成長すると予想されます。予測期間で予想される成長は、運動失調症の医薬品開発の加速、希少疾患調査への投資の増加、精密医療アプローチの採用、患者擁護への注目の高まり、運動失調症の遺伝的基盤の理解の深まりによるものと考えられます。予測期間に予想される主な動向には、運動失調症管理へのデジタルヘルスソリューションの統合、運動失調症治療のための遺伝子治療の開発、共同調査イニシアチブの増加、患者中心のケアモデルの重視、運動失調症相談に対する遠隔医療の採用などが含まれます。

アルコール消費量の増加は、予見可能な将来において運動失調症市場の拡大を後押しする重要な促進力となると見込まれています。慢性的なアルコールの誤用は、小脳変性と呼ばれる後天性の有毒な運動失調症の主な原因であり、蔓延する運動失調状態の一因となっています。アルコール依存症の人は、下肢の姿勢振戦や歩行運動失調症などの症状を示すことがよくあります。例えば、Kirin Holdings Company Limitedが2022年12月に開示した「2021年の世界ビール消費量報告書」のデータによると、世界のビール消費量は大幅に増加し、2021年の合計約1億8,560万キロリットル（前年比4.0％増）となりました。この急増は、COVID-19後のシナリオの影響もあり、約713万キロリットルの増加を記録し、ビールの総消費量は約1億8,560万キロリットルに達しました。その結果、アルコール消費量の増加が運動失調症市場の成長を促進する触媒として機能します。

ヘルスケア支出の急増により、今後数年間で運動失調症市場の拡大が促進されると予想されます。ヘルスケア支出の増加には、運動失調症関連の症状を対象とした革新的な治療法や療法の高度な調査、開発、利用可能性へのリソースの配分が含まれます。ヘルスケア費の増加に伴い、運動失調症の理解と管理を強化するための協調的な取り組みが行われています。たとえば、メディケア・メディケイド・サービスセンターが2022年3月に発表した2021年から2030年の国民医療支出（NHE）報告書の予測では、国民医療支出が年間平均5.1％増加し、約6兆8,000億米ドルまで大幅に増加すると予想されています。その結果、ヘルスケア支出の上昇軌道は、運動失調症市場内で観察される成長の促進力として機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の運動失調症市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の運動失調症の市場規模実績と成長、2018年～2023年
  • 世界の運動失調症の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の運動失調症市場、タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • フリードライヒ失調症
  • 運動失調-毛細血管拡張症
  • エピソード性運動失調症
  • その他のタイプ
  • 世界の運動失調症市場、製品別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 治療
  • 診断
  • 世界の運動失調症市場、剤形別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 固体
  • 液体
  • その他の剤形
  • 世界の運動失調症市場、投与経路別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 経口
  • 非経口
  • 他の投与経路
  • 世界の運動失調症市場、エンドユーザー別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 病院
  • クリニック
  • 在宅ヘルスケア
  • その他のエンドユーザー

第7章 地域と国の分析

  • 世界の運動失調症市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 世界の運動失調症市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 運動失調症市場の競合情勢
  • 運動失調症市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc.
    • Bayer AG

第31章 その他の大手と革新的な企業

  • Novartis AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Boehringer Ingelheim International GmbH
  • Merck KgaA
  • Viatris Inc.
  • Teva Pharmaceutical
  • Otsuka Pharmaceutical Co. Ltd.
  • Mylan NV
  • Celgene Corporation
  • Vertex Pharmaceuticals Incorporated

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13549

Ataxia is a neurological disorder characterized by irregular movements and challenges with balance, stemming from a lack of muscular control and coordination. This condition affects various body regions, including limbs, speech, and eye movements.

The primary types of ataxias encompass Friedreich's ataxia, ataxia-telangiectasia, episodic ataxia, and others. Friedreich's ataxia is a rare genetic disorder that disrupts movement and progressively damages the nervous system. Treatment options and diagnostic methods are available for managing this condition. These treatments come in different forms, including solids and liquids, and can be administered through various routes such as oral and parenteral. The end-users for these treatments include hospitals, clinics, home healthcare, and others.

The ataxia market research report is one of a series of new reports from The Business Research Company that provides ataxia market statistics, including ataxia industry global market size, regional shares, competitors with a ataxia market share, detailed ataxia market segments, market trends and opportunities, and any further data you may need to thrive in the ataxia industry. This ataxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ataxia market size has grown strongly in recent years. It will grow from $33.78 billion in 2023 to $37.01 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be ascribed to factors such as the limited availability of treatment options, advancements in neurological research, heightened awareness of rare diseases, ongoing evolution of diagnostic technologies, and an increased focus on understanding genetic factors.

The ataxia market size is expected to see strong growth in the next few years. It will grow to $51.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period can be attributed to the accelerated development of drugs for ataxia, increased investments in rare disease research, the adoption of precision medicine approaches, a heightened focus on patient advocacy, and a growing understanding of the genetic basis of ataxia. Major trends expected in the forecast period include the integration of digital health solutions in ataxia management, the development of gene therapies for ataxia treatment, a rise in collaborative research initiatives, an emphasis on patient-centric care models, and the adoption of telemedicine for ataxia consultations.

The escalation in alcohol consumption is poised to be a significant driver behind the expansion of the ataxia market in the foreseeable future. Chronic alcohol misuse, a leading cause of acquired toxic ataxia termed cerebellar degeneration, contributes to prevalent ataxic conditions. Individuals with alcoholism often exhibit symptoms such as lower limb postural tremors and gait ataxia. For example, data from the Global Beer Consumption Report for 2021, disclosed by Kirin Holdings Company Limited in December 2022, indicated a substantial increase in worldwide beer consumption, totaling about 185.60 million kiloliters in 2021-a 4.0% rise from the preceding year. This surge, partly influenced by the post-COVID-19 scenario, marked an elevation of roughly 7.13 million kiloliters, driving the total beer consumption to approximately 185.6 million kiloliters. Consequently, the heightened alcohol consumption serves as a catalyst propelling growth within the ataxia market.

The upsurge in healthcare expenditure is anticipated to drive the expansion of the ataxia market in the coming years. Elevated healthcare spending encompasses the allocation of resources toward advanced research, development, and accessibility of innovative treatments and therapies targeting ataxia-related conditions. As healthcare expenditures rise, there's a concerted effort to enhance the understanding and management of ataxia. For instance, projections from the 2021-2030 National Health Expenditure (NHE) report, released by the Centers for Medicare & Medicaid Services in March 2022, indicated an average annual increase of 5.1% in national health spending, foreseeing a substantial rise to approximately $6.8 trillion by 2030. Consequently, the upward trajectory in healthcare expenditure acts as a driving force behind the growth observed within the ataxia market.

Innovative product development is a prominent trend gaining momentum within the ataxia market. Leading companies within this domain are committed to introducing novel products or drugs to fortify their market presence. A case in point is the announcement made by Reata Pharmaceuticals in February 2023, unveiling the FDA approval of SKYCLARYS (omavaloxolone). This groundbreaking medication stands as the inaugural drug indicated specifically for individuals with Friedreich's ataxia, encompassing adults and adolescents aged 16 and above. Notably, treatment with SKYCLARYS demonstrated a statistically significant reduction in mFARS (modified Friedreich's Ataxia Rating Scale) scores at Week 48, evidencing diminished impairment compared to a placebo. Friedreich's ataxia, an exceedingly rare inherited neurological disorder, is commonly diagnosed during adolescence.

Strategic partnerships have emerged as another pivotal trend within the ataxia market, as major players focus on forging alliances to bolster their market positioning. An illustrative example is the collaboration between CRISPR Therapeutics, a Switzerland-based biopharmaceutical company, and Capsida Biotherapeutics Inc., a US-based biotechnology company, announced in June 2021. This collaboration is centered on researching, developing, manufacturing, and commercializing novel gene editing therapies targeting Friedreich's ataxia and familial amyotrophic lateral sclerosis (ALS). Under this agreement, CRISPR Therapeutics leads the research and development efforts for the Friedreich's ataxia program, overseeing gene-editing activities for both programs. Capsida, on the other hand, spearheads the research and development initiatives for the ALS program, focusing on capsid engineering for both therapeutic programs.

In December 2022, Solid Biosciences Inc., a US-based biotech company, successfully completed the acquisition of AavantiBio Inc. for an undisclosed amount. This strategic move allows Solid Biosciences Inc. to gain access to AavantiBio's portfolio of neuromuscular and cardiac programs. Notable assets acquired include the differentiated gene transfer candidate SGT-003 for Duchenne, the gene transfer candidate AVB-202 for Friedreich's ataxia, the gene transfer candidate AVB-401 for BAG3-mediated dilated cardiomyopathy, along with additional assets designed for the treatment of unspecified cardiac diseases. AavantiBio Inc. is recognized as a leading gene therapy company in the United States, specializing in the treatment of Friedreich's ataxia and cardiovascular diseases.

Major companies operating in the ataxia market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Viatris Inc., Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Celgene Corporation, Vertex Pharmaceuticals Incorporated, Banner Health, UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Genentech Inc., Ipsen Biopharmaceuticals Inc., Aurobindo Pharma Limited, Apotex Inc., Amneal Pharmaceuticals LLC, Biogen Inc., Lupin Limited

North America was the largest region in the ataxia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the ataxia market report during the forecast period. The regions covered in the ataxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ataxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ataxia market consists of revenues earned by entities by providing serotonergic therapy, occupational therapy, vestibular rehabilitation, and hyperbaric oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ataxia market also includes sales of adaptive devices including walkers or canes, acetazolamide, and amantadine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ataxia Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ataxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ataxia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ataxia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Friedreich's Ataxia; Ataxia-telangiectasia; Episodic Ataxia; Other Types
  • 2) By Product: Treatment; Diagnosis
  • 3) By Dosage Form: Solid; Liquids; Other Dosage Forms
  • 4) By Route of Administration: Oral; Parenteral; Other Routes of Administration
  • 5) By End User: Hospital; Clinics; Home Healthcare; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; AbbVie Inc.; Bayer AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ataxia Market Characteristics

3. Ataxia Market Trends And Strategies

4. Ataxia Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Ataxia Market Size and Growth

  • 5.1. Global Ataxia Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Ataxia Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Ataxia Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ataxia Market Segmentation

  • 6.1. Global Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Friedreich's Ataxia
  • Ataxia-telangiectasia
  • Episodic Ataxia
  • Other Types
  • 6.2. Global Ataxia Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Treatment
  • Diagnosis
  • 6.3. Global Ataxia Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Solid
  • Liquids
  • Other Dosage Forms
  • 6.4. Global Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes of Administration
  • 6.5. Global Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Clinics
  • Home Healthcare
  • Other End-Users

7. Ataxia Market Regional And Country Analysis

  • 7.1. Global Ataxia Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Ataxia Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ataxia Market

  • 8.1. Asia-Pacific Ataxia Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ataxia Market

  • 9.1. China Ataxia Market Overview
  • 9.2. China Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ataxia Market

  • 10.1. India Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ataxia Market

  • 11.1. Japan Ataxia Market Overview
  • 11.2. Japan Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ataxia Market

  • 12.1. Australia Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ataxia Market

  • 13.1. Indonesia Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ataxia Market

  • 14.1. South Korea Ataxia Market Overview
  • 14.2. South Korea Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ataxia Market

  • 15.1. Western Europe Ataxia Market Overview
  • 15.2. Western Europe Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ataxia Market

  • 16.1. UK Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ataxia Market

  • 17.1. Germany Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ataxia Market

  • 18.1. France Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ataxia Market

  • 19.1. Italy Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ataxia Market

  • 20.1. Spain Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ataxia Market

  • 21.1. Eastern Europe Ataxia Market Overview
  • 21.2. Eastern Europe Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ataxia Market

  • 22.1. Russia Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ataxia Market

  • 23.1. North America Ataxia Market Overview
  • 23.2. North America Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ataxia Market

  • 24.1. USA Ataxia Market Overview
  • 24.2. USA Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ataxia Market

  • 25.1. Canada Ataxia Market Overview
  • 25.2. Canada Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ataxia Market

  • 26.1. South America Ataxia Market Overview
  • 26.2. South America Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ataxia Market

  • 27.1. Brazil Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ataxia Market

  • 28.1. Middle East Ataxia Market Overview
  • 28.2. Middle East Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ataxia Market

  • 29.1. Africa Ataxia Market Overview
  • 29.2. Africa Ataxia Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Ataxia Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Ataxia Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ataxia Market Competitive Landscape And Company Profiles

  • 30.1. Ataxia Market Competitive Landscape
  • 30.2. Ataxia Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bayer AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Ataxia Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. GlaxoSmithKline plc
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Eli Lilly and Company
  • 31.7. Gilead Sciences Inc.
  • 31.8. Boehringer Ingelheim International GmbH
  • 31.9. Merck KgaA
  • 31.10. Viatris Inc.
  • 31.11. Teva Pharmaceutical
  • 31.12. Otsuka Pharmaceutical Co. Ltd.
  • 31.13. Mylan N.V.
  • 31.14. Celgene Corporation
  • 31.15. Vertex Pharmaceuticals Incorporated

32. Global Ataxia Market Competitive Benchmarking

33. Global Ataxia Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ataxia Market

35. Ataxia Market Future Outlook and Potential Analysis

  • 35.1 Ataxia Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Ataxia Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Ataxia Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer